Bristol Myers Squibb (BMY) is undervalued and poised for growth, with strong dividends and robust financials. Read here for more analysis.

Fossils can reveal far more than the shapes of ancient creatures. Molecules preserved inside old animal bones provide clues about past diseases, what those animals ate, and the climates they lived in.

President Donald Trump has secured a sweeping set of drug pricing concessions that reach deep into both Medicare and Medicaid, reshaping how some of the most expensive medicines will be paid for in ...

One of the most detailed 3D maps of how the human chromosomes are organized and folded within a cell's nucleus is published ...

With the passing of Professor Adamu Baikie on Friday, 12, 2025, Nigeria and the broader African academic community have lost a true architect of modern education. He was ...

Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing.

BMS signed a multiyear agreement with antibody specialist Harbour BioMed, which has operations in the US, the Netherlands, ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory conditions. The target applies to a range of potential indications, from ...

Gestione, sostenibilità e valorizzazione dell’operazione immobiliare. Imprenditorialità innovativa e industrializzazione del ...

Battery cell layout can reduce risk, but it cannot compensate for deeper engineering and integration failures.

Propelled by a flurry of dealmaking late in the year, M&As in 2025 ended on a strong note, with high activity expected to continue in 2026.